Grants and Contributions:
Title:
Identifying sepsis and predicting sepsis severity in the emergency room: Multi-centre, international clinical study to refine novel gene signature
Agreement Number:
905969
Agreement Value:
$50,000.00
Agreement Date:
May 1, 2018 - May 31, 2019
Description:
Sepset is developing a blood test to provide doctors with earlier, more reliable, and actionable data to identify sepsis and predict sepsis severity. This project is to statistically validate and refine a gene signature that will be compatible in a clinical platform.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6T 1Z3
Reference Number:
172-2018-2019-Q1-905969
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
805251790
Recipient Type:
For-profit organization
Recipient's Operating Name:
Sepset
Recipient's Legal Name:
Sepset Biosciences Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
5419